Hopium Raises €1 Million Through Convertible Bonds and Warns of Heavy Dilution
In a press release published on November 16, 2026, the hydrogen fuel cell electric powertrain company activated the first tranche of the convertible bond financing intended to support its recovery plan. The company itself highlights the dilutive nature of this instrument for its shareholders.
A First Tranche Linked to the July Recovery Plan
The drawdown covers a nominal amount of €1,000,000. It falls under the convertible bond financing agreement (OCA) signed with Atlas Capital Market on June 26, 2026, which the company refers to as the “2026 Financing”.
This financing supports the amended recovery plan approved by the Paris Court of Economic Activities in its judgment of July 28, 2026. Hopium states that it is “continuously working to reduce its expenses and optimize its cash management”.
Atlas was already its counterparty under the agreement concluded on November 3, 2026, which concerned the settlement of approximately €7.9 million in residual bond debt from the 2025 Financing, through the issuance of new shares and warrants (BSA).
Conversion Indexed to the Share Price, Accompanied by Warnings from the Company
The OCAs have a maturity of 24 months from their issuance and carry a coupon of 3-month Euribor + 5% per year. They are subscribed at 92% of their nominal value, which is set at €10,000.
The holder may request conversion at any time, and conversion becomes mandatory at the latest at maturity. The conversion price equals 100% of the volume-weighted average price on a trading session chosen by the investor from among the 10 consecutive business days preceding the conversion notice, and may not be lower than the nominal value of the share.
The company draws attention to the significant dilution risk associated with these conversions. It specifies that the shares resulting from conversion are generally sold on the market within very short periods, which could create strong downward pressure on the share price.
Shareholders may therefore suffer a loss of capital and substantial dilution due to the large number of securities issued in favor of Atlas Special Opportunities II. Hopium invites investors to be “highly vigilant”, particularly in the face of successive dilutive transactions.